Company profile
Alentis Therapeutics company profile
Alentis Therapeutics, the CLDN1 company, is a clinical-stage biotech investigating novel therapeutics for CLDN1+ cancers. Alentis is the pioneering business in the use of anti-CLDN1 ADCs and antibodies to modify and reverse the progression of certain diseases.
Business identity
- Website
- https://alentis.ch/
- Contact email
- [email protected]
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 51-100 employees
- Founded
- 2019-01-01, Year
Headquarters
- Headquarters
- Allschwil, Basel-Landschaft, Switzerland
- Postal code
- 4123
- Country code
- CH
- Continent
- Europe